American Well (AMWL) 10-Q 5 Aug 22 2022 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2022	Jul. 31, 2022
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Trading Symbol	AMWL
Entity Registrant Name	American Well Corporation
Entity Central Index Key	0001393584
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Security Exchange Name	NYSE
Title of 12(b) Security	Class A common stock,par value of $0.01 per share
Entity File Number	001-39515
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-5009396
Entity Address, Address Line One	75 State Street
Entity Address, Address Line Two	26th Floor
Entity Address, City or Town	Boston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02109
City Area Code	617
Local Phone Number	204-3500
Common Class A [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		240,621,761
Common Class B [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		27,390,397
Common Class C [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		5,555,555

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 257,189	$ 746,416
Investments	372,880
Accounts receivable ($82 and $2,054, from related parties and net of allowances of $1,452 and $1,809, respectively)	44,675	51,375
Inventories	7,921	7,530
Deferred contract acquisition costs	1,781	1,697
Prepaid expenses and other current assets	22,148	20,278
Total current assets	706,594	827,296
Restricted cash	795	795
Property and equipment, net	1,498	2,235
Goodwill	433,840	442,761
Intangible assets, net	136,434	152,409
Operating lease right-of-use asset	14,511	16,422
Deferred contract acquisition costs, net of current portion	2,202	2,028
Other assets	1,233	1,722
Investment in minority owned joint venture	1,366	168
Total assets	1,298,473	1,445,836
Current liabilities:
Accounts payable	5,490	12,156
Accrued expenses and other current liabilities	43,649	58,711
Operating lease liability, current	3,174	1,918
Deferred revenue ($867 and $1,860 from related parties, respectively)	63,971	68,841
Total current liabilities	116,284	141,626
Other long-term liabilities	3,677	5,136
Contingent consideration liabilities, net of current portion		16,450
Operating lease liability, net of current portion	12,842	14,694
Deferred revenue, net of current portion ($16 and $22 from related parties, respectively)	4,777	7,055
Total liabilities	137,580	184,961
Commitments and contingencies (Note 11)
Stockholders’ equity:
Preferred stock, $0.01 par value; 100,000,000 shares authorized, no shares issued or outstanding as of June 30, 2022 and as of December 31, 2021
Common stock, $0.01 par value; 1,000,000,000 Class A shares authorized, 240,397,065 and 229,402,453 shares issued and outstanding, respectively; 100,000,000 Class B shares authorized, 27,390,397 and 26,913,579 shares issued and outstanding, respectively; 200,000,000 Class C shares authorized 5,555,555 issued and outstanding as of June 30, 2022 and as of December 31, 2021	2,734	2,620
Additional paid-in capital	2,108,576	2,054,275
Accumulated other comprehensive income	(20,845)	(6,353)
Accumulated deficit	(950,466)	(811,284)
Total American Well Corporation stockholders’ equity	1,139,999	1,239,258
Non-controlling interest	20,894	21,617
Total stockholders’ equity	1,160,893	1,260,875
Total liabilities and stockholders’ equity	$ 1,298,473	$ 1,445,836

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Accounts receivable from related parties	$ 82	$ 2,054
Accounts receivable net of allowances	1,452	1,809
Deferred revenue from related parties current	867	1,860
Deferred revenue from related parties non current	$ 16	$ 22
Preferred Stock, Par Value	$ 0.01	$ 0.01
Preferred Stock, Shares Authorized	100,000,000	100,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Shares Authorized	1,300,000,000
Common Stock, Shares, Issued	273,343,017
Common Stock, Shares, Outstanding	273,343,017
Common Class A [Member]
Common Stock, Par Value	$ 0.01	$ 0.01
Common Stock, Shares Authorized	1,000,000,000	1,000,000,000
Common Stock, Shares, Issued	240,397,065	229,402,453
Common Stock, Shares, Outstanding	240,397,065	229,402,453
Common Class B [Member]
Common Stock, Par Value	$ 0.01	$ 0.01
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	27,390,397	26,913,579
Common Stock, Shares, Outstanding	27,390,397	26,913,579
Common Class C [Member]
Common Stock, Par Value	$ 0.01	$ 0.01
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Shares, Issued	5,555,555	5,555,555
Common Stock, Shares, Outstanding	5,555,555	5,555,555

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations And Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue
( $1,163, $1,462, $2,377 and $3,089 from related parties, respectively)	$ 64,516	$ 60,217	$ 128,748	$ 117,816
Costs and operating expenses:
Costs of revenue, excluding depreciation and amortization of intangible assets	36,497	33,889	73,262	69,594
Research and development	37,067	22,378	74,548	45,418
Sales and marketing	18,721	14,789	39,875	28,521
General and administrative	34,911	24,212	67,627	45,566
Depreciation and amortization expense	6,724	2,484	13,322	4,990
Total costs and operating expenses	133,920	97,752	268,634	194,089
Loss from operations	(69,404)	(37,535)	(139,886)	(76,273)
Interest income and other (expense) income, net	764	224	872	285
Loss before expense from income taxes and loss from equity method investment	(68,640)	(37,311)	(139,014)	(75,988)
Benefit (Expense) from income taxes	(461)	(103)	(129)	(412)
Loss from equity method investment	(551)	(722)	(762)	(1,541)
Net loss	(69,652)	(38,136)	(139,905)	(77,941)
Net loss attributable to non-controlling interest	(507)	(277)	(723)	(894)
Net loss attributable to American Well Corporation	$ (69,145)	$ (37,859)	$ (139,182)	$ (77,047)
Net loss per share attributable to common stockholders, basic	$ (0.25)	$ (0.15)	$ (0.51)	$ (0.31)
Net loss per share attributable to common stockholders, diluted	$ (0.25)	$ (0.15)	$ (0.51)	$ (0.31)
Weighted-average common shares outstanding, basic	273,320,740	249,366,652	273,615,031	246,471,733
Weighted-average common shares outstanding, diluted	273,320,740	249,366,652	273,615,031	246,471,733
Net loss	$ (69,652)	$ (38,136)	$ (139,905)	$ (77,941)
Other comprehensive income (loss), net of tax:
Unrealized (loss) gain on available-for-sale investments	(111)	(119)	(1,362)	(85)
Foreign currency translation	(10,179)	(20)	(13,130)	(72)
Comprehensive loss	(79,942)	(38,275)	(154,397)	(78,098)
Less: Comprehensive loss attributable to non-controlling interest	(507)	(277)	(723)	(894)
Comprehensive loss attributable to American Well Corporation	$ (79,435)	$ (37,998)	$ (153,674)	$ (77,204)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations And Comprehensive Loss (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Revenue from Related Parties	$ 1,163	$ 1,462	$ 2,377	$ 3,089

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Equity (Deficit) [Member]	American Well Corporation Stockholder Equity (Deficit) [Member]	Noncontrolling Interest [Member]
Beginning balance at Dec. 31, 2020	$ 1,246,197	$ 2,357	$ (37,568)	$ 1,841,405	$ 297	$ (582,359)	$ 1,224,132	$ 22,065
Beginning balance (in shares) at Dec. 31, 2020		235,604,105
Exercise of common stock options	10,130	$ 34		10,096			10,130
Exercise of common stock options, Shares		3,474,375
Vesting of restricted stock units		$ 9		(9)
Vesting of restricted stock units ,Shares		853,842
Retirement of treasury stock			37,568	(15)		(37,553)
Shares withheld related to net share settlement and retired treasury stock in 2021	(9,771)	$ (4)		4		(9,771)	(9,771)
Shares withheld related to net share settlement and retired treasury stock, Shares		(402,060)
Stock-based compensation expense	8,642			8,642			8,642
Currency translation adjustment	(52)				(52)		(52)
Unrealized gains (losses) on available-for-sale securities, net of tax	34				34		34
Net loss	(39,805)					(39,188)	(39,188)	(617)
Ending balance at Mar. 31, 2021	1,215,375	$ 2,396		1,860,123	279	(668,871)	1,193,927	21,448
Ending balance, Shares at Mar. 31, 2021		239,530,262
Beginning balance at Dec. 31, 2020	1,246,197	$ 2,357	$ (37,568)	1,841,405	297	(582,359)	1,224,132	22,065
Beginning balance (in shares) at Dec. 31, 2020		235,604,105
Currency translation adjustment	(72)
Unrealized gains (losses) on available-for-sale securities, net of tax	(85)
Net loss	(77,941)
Ending balance at Jun. 30, 2021	1,192,643	$ 2,422		1,877,497	140	(708,587)	1,171,472	21,171
Ending balance, Shares at Jun. 30, 2021		242,118,903
Beginning balance at Mar. 31, 2021	1,215,375	$ 2,396		1,860,123	279	(668,871)	1,193,927	21,448
Beginning balance (in shares) at Mar. 31, 2021		239,530,262
Exercise of common stock options	6,674	$ 18		6,656			6,674
Exercise of common stock options, Shares		1,812,491
Vesting of restricted stock units		$ 9		(9)
Vesting of restricted stock units ,Shares		844,900
Shares withheld related to net share settlement and retired treasury stock in 2021	(1,857)	$ (1)		1		(1,857)	(1,857)
Shares withheld related to net share settlement and retired treasury stock, Shares		(68,750)
Stock-based compensation expense	10,726			10,726			10,726
Currency translation adjustment	(20)				(20)		(20)
Unrealized gains (losses) on available-for-sale securities, net of tax	(119)				(119)		(119)
Net loss	(38,136)					(37,859)	(37,859)	(277)
Ending balance at Jun. 30, 2021	1,192,643	$ 2,422		1,877,497	140	(708,587)	1,171,472	21,171
Ending balance, Shares at Jun. 30, 2021		242,118,903
Beginning balance at Dec. 31, 2021	1,260,875	$ 2,620		2,054,275	(6,353)	(811,284)	1,239,258	21,617
Beginning balance (in shares) at Dec. 31, 2021		261,871,587
Exercise of common stock options	2,465	$ 10		2,455			2,465
Exercise of common stock options, Shares		976,644
Vesting of restricted stock units		$ 14		(14)
Vesting of restricted stock units ,Shares		1,398,305
Issuance of stock under employee stock purchase plan	1,501	$ 4		1,497			1,501
Issuance of stock under employee stock purchase plan,Shares		425,114
Issuance of common stock related to Conversa/SilverCloud earn-out settlement	4,298	$ 10		4,288			4,298
Issuance of common stock related to Conversa/SilverCloud earn-out settlement, Shares		1,020,964
Stock-based compensation expense	12,085			12,085			12,085
Capital contributed by selling shareholders of acquired businesses	2,019			2,019			2,019
Currency translation adjustment	(2,951)				(2,951)		(2,951)
Unrealized gains (losses) on available-for-sale securities, net of tax	(1,251)				(1,251)		(1,251)
Net loss	(70,253)					(70,037)	(70,037)	(216)
Ending balance at Mar. 31, 2022	1,208,788	$ 2,658		2,076,605	(10,555)	(881,321)	1,187,387	21,401
Ending balance, Shares at Mar. 31, 2022		265,692,614
Beginning balance at Dec. 31, 2021	1,260,875	$ 2,620		2,054,275	(6,353)	(811,284)	1,239,258	21,617
Beginning balance (in shares) at Dec. 31, 2021		261,871,587
Currency translation adjustment	(13,130)
Unrealized gains (losses) on available-for-sale securities, net of tax	(1,362)
Net loss	(139,905)
Ending balance at Jun. 30, 2022	1,160,893	$ 2,734		2,108,576	(20,845)	(950,466)	1,139,999	20,894
Ending balance, Shares at Jun. 30, 2022		273,343,017
Beginning balance at Mar. 31, 2022	1,208,788	$ 2,658		2,076,605	(10,555)	(881,321)	1,187,387	21,401
Beginning balance (in shares) at Mar. 31, 2022		265,692,614
Exercise of common stock options	1,926	$ 10		1,916			1,926
Exercise of common stock options, Shares		1,083,571
Vesting of restricted stock units		$ 16		(16)
Vesting of restricted stock units ,Shares		1,606,976
Issuance of common stock related to Conversa/SilverCloud earn-out settlement	12,945	$ 50		12,895			12,945
Issuance of common stock related to Conversa/SilverCloud earn-out settlement, Shares		4,959,856
Receipt of Section 16(b) disgorgement	295			295			295
Stock-based compensation expense	14,907			14,907			14,907
Capital contributed by selling shareholders of acquired businesses	1,974			1,974			1,974
Currency translation adjustment	(10,179)				(10,179)		(10,179)
Unrealized gains (losses) on available-for-sale securities, net of tax	(111)				(111)		(111)
Net loss	(69,652)					(69,145)	(69,145)	(507)
Ending balance at Jun. 30, 2022	$ 1,160,893	$ 2,734		$ 2,108,576	$ (20,845)	$ (950,466)	$ 1,139,999	$ 20,894
Ending balance, Shares at Jun. 30, 2022		273,343,017

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Cash flows from operating activities:
Net loss	$ (69,652)	$ (70,253)	$ (38,136)	$ (39,805)	$ (139,905)	$ (77,941)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense					13,132	4,990
Provisions for credit losses					(308)	(57)	$ 714
Amortization of deferred contract acquisition costs					847	731
Amortization of deferred contract fulfillment costs					288	351
Noncash compensation costs incurred by selling shareholders					3,993
Stock-based compensation expense					27,598	19,368
Loss on equity method investment	551		722		762	1,541
Deferred income taxes					(1,164)
Changes in operating assets and liabilities, net of acquisition:
Accounts receivable					5,763	9,809
Inventories					(391)	199
Deferred contract acquisition costs					(1,135)	(618)
Prepaid expenses and other current assets					(1,714)	284
Other assets					489	184
Accounts payable					(6,525)	(624)
Accrued expenses and other current liabilities					(490)	(16,063)
Other long-term liabilities					(15)	(38)
Deferred revenue					(6,624)	(9,506)
Net cash used in operating activities					(105,399)	(67,390)
Cash flows from investing activities:
Purchases of property and equipment					(58)	(283)
Investment in less than majority owned joint venture					(1,960)	(2,548)
Purchases of investments					(499,223)
Proceeds from sales and maturities of investments					124,981	100,000
Net cash used in and provided by investing activities					(376,260)	97,169
Cash flows from financing activities:
Proceeds from exercise of common stock options					4,465	16,733
Proceeds from employee stock purchase plan					1,501
Payments for the purchase of treasury stock						(11,628)
Payment of deferred offering costs						(1,613)
Proceeds from Section 16(b) disgorgement					295
Payment of contingent consideration					(11,790)
Net cash used in and provided by financing activities					(5,529)	3,492
Effect of exchange rates changes on cash, cash equivalents, and restricted cash					(2,039)
Net decrease in cash, cash equivalents, and restricted cash					(489,227)	33,271
Cash, cash equivalents, and restricted cash at beginning of period		$ 747,211		$ 942,711	747,211	942,711	942,711
Cash, cash equivalents, and restricted cash at end of period	257,984		975,982		257,984	975,982	747,211
Cash, cash equivalents, and restricted cash at end of period:
Cash and cash equivalents	257,189		975,187		257,189	975,187	746,416
Restricted cash	795		795		795	795
Total cash, cash equivalents, and restricted cash at end of period	$ 257,984		$ 975,982		257,984	975,982	$ 747,211
Supplemental disclosure of cash flow information:
Cash (refunded) paid for income taxes					13	955
Supplemental disclosure of non-cash investing and financing activities:
Issuance of common stock in settlement of earnout					$ 17,243
Receivable related to exercise of common stock options						$ 71

Organization and Description of

Organization and Description of Business	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	1. Organization and Description of Business Description of Business American Well Corporation (the “Company”) was incorporated under the laws of the State of Delaware in June 2006. The Company is headquartered in Boston, Massachusetts. The Company is a leading enterprise software company enabling digital delivery of care for healthcare’s key stakeholders. The Company empowers our clients with the core technology and services necessary to successfully develop and distribute virtual care programs that meet their strategic, operational, financial and clinical objectives under their own brands. Acquisitions On August 9, 2021 and August 27, 2021 , the Company completed the acquisitions of Conversa Health Inc. (“Conversa”) and SilverCloud Health Holdings, Inc. (“SilverCloud”), respectively (together, the “Acquisitions”). Conversa is a leader in automated virtual healthcare. SilverCloud is a leading digital mental health platform. See Note 7 “Business Combinations”. Liquidity and Capital Resources The Company expects that its cash, cash equivalents and investments balance as of June 30, 2022 of $ 630,069 will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next twelve months.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies There have been no material changes to the significant accounting policies described in the Company’s Form 10-K for the fiscal year ended December 31, 2021, that have had a material impact on the consolidated financial statements and related notes. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary for the fair statement of the Company’s the financial position, results of operations and cash flows at the dates and for the periods indicated. The interim results for the three and six months ended June 30, 2022 are not necessarily indicative of results for the full 2022 calendar year or any other future interim periods. The information included in the interim financial statements should be read in conjunction with the annual consolidated financial statements and accompanying notes included in the Form 10-K. The unaudited condensed consolidated financial statements include the accounts of American Well Corporation, its wholly-owned subsidiaries, those of professional corporations, which represent variable interest entities in which American Well has an interest and is the primary beneficiary (“PC”), and National Telehealth Network (“NTN”), an entity in which American Well controls fifty percent or more of the voting shares (see Note 4). Intercompany accounts and transactions have been eliminated in consolidation. The Company’s reporting currency is the U.S. dollar. The Company determines the functional currency of each subsidiary based on the currency of the primary economic environment in which each subsidiary operates. Items included in the financial statements of such subsidiaries are measured using that functional currency. Foreign currency denominated monetary assets and liabilities are remeasured into U.S. dollars at current exchange rates and foreign currency denominated nonmonetary assets and liabilities are remeasured into U.S. dollars at historical exchange rates. Gains or losses from foreign currency remeasurement and settlements are included in interest income and other income (expense), net in the condensed consolidated statements of operations and comprehensive loss. For consolidated entities where American Well owns or is exposed to less than 100 % of the economics, the net loss attributable to noncontrolling interests is recorded in the condensed consolidated statements of operations and comprehensive loss equal to the percentage of the economic or ownership interest retained in each entity by the respective non-controlling party. The noncontrolling interests are presented as a separate component of stockholders’ deficit in the condensed consolidated balance sheets. Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reported periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, revenue recognition, the estimated customer relationship period that is used in the amortization of deferred contract acquisition costs, the valuation of assets and liabilities acquired in business combinations, the useful lives of intangible assets and property and equipment and the valuation of common stock. The Company bases its estimates on historical experience, known trends, and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. Due to the COVID-19 global pandemic, the global economy and financial markets have been disrupted and there is a significant amount of uncertainty about the length and severity of the consequences caused by the pandemic. The Company has considered information available to it as of the date of issuance of these financial statements and has not experienced any significant impact to its estimates and assumptions as a result of the COVID-19 pandemic. On an ongoing basis, the Company will continue to closely monitor the COVID-19 impact on its estimates and assumptions. Segment Information The Company’s chief operating decision makers (CODMs), its two Chief Executive Officers, review financial information presented on a consolidated basis for purposes of allocating resources and evaluating financial performance. The Company operates and manages its business as one reportable and operating segment. In addition, substantially all of the Company’s revenue and long-lived assets are attributable to operations in the United States for all periods presented. Variable Interest Entities The Company evaluates its ownership, contractual and other interests in entities to determine if it has any variable interest in a variable interest entity (“VIE”). These evaluations are complex and involve judgment. If the Company determines that an entity in which it holds a contractual or ownership interest is a VIE and that the Company is the primary beneficiary, the Company consolidates such entity in its condensed consolidated financial statements. The primary beneficiary of a VIE is the party that meets both of the following criteria: (i) has the power to make decisions that most significantly affect the economic performance of the VIE; and (ii) has the obligation to absorb losses or the right to receive benefits that in either case could potentially be significant to the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company’s involvement with a VIE will cause the consolidation conclusion to change. Changes in consolidation status are applied prospectively. The aggregate carrying value of total assets and total liabilities included on the condensed consolidated balance sheets for the PCs after elimination of intercompany transactions were $ 26,879 and $ 1,508 , respectively, as of June 30, 2022 and $ 29,770 and $ 1,485 , respectively as of December 31, 2021. Total revenue included on the condensed consolidated statements of operations and comprehensive loss for the PCs after elimination of intercompany transactions was $ 17,400 and $ 17,585 for the three ended June 30, 2022 and 2021, respectively. Net loss included on the condensed consolidated statements of operations and comprehensive loss was not material for the three months ended June 30, 2022 and 2021. Total revenue included on the condensed consolidated statements of operations and comprehensive loss for the PCs after elimination of intercompany transactions was $ 35,792 and $ 35,154 for the six months ended June 30, 2022 and 2021, respectively. Net loss included on the condensed consolidated statements of operations and comprehensive loss was not material for the six months ended June 30, 2022 and 2021 Investment in Minority Owned Joint Venture The Company and Cleveland Clinic partnered to form a joint venture, under the name CCAW, JV LLC, to provide broad access to comprehensive and high acuity care services via digital care delivery. The Company does not have a controlling financial interest in CCAW, JV LLC, but it does have the ability to exercise significant influence over the operating and financial policies of CCAW, JV LLC. Therefore, the Company accounts for its investment in CCAW, JV LLC using the equity method of accounting. The joint venture is considered a variable interest entity under ASC 810-10, but the Company is not the primary beneficiary as it does not have the power to direct the activities of the joint venture that most significantly impact its performance. The Company’s evaluation of ability to impact performance is based on Cleveland Clinic’s managing directors and Cleveland Clinic’s ability to appoint and remove the chairperson who has the ability to cast the tie breaking vote on the most significant activities. In 2020 the Company contributed $ 2,940 as its initial investment for a 49 % interest in CCAW, JV LLC. The agreement also requires aggregate total capital contributions by the Company up to an additional $ 11,800 in two phases, which is yet to be defined. During the three months ended March 31, 2021, the Company made a capital contribution of $ 2,548 , related to a portion of the phase one capital commitment. In April 2022 the Company made a capital contribution of $ 1,960 related to a portion of the phase one capital commitment. For the three months ended June 30, 2022 and 2021, the Company recognized a loss of $ 551 and $ 722 as its proportionate share of the joint venture’s results of operations, respectively. For the six months ended June 30, 2022 and 2021, the Company recognized a loss of $ 762 and $ 1,541 , respectively. Accordingly, the carrying value of the equity method investment as of June 30, 2022 and December 31, 2021 was $ 1,366 and $ 168 , respectively. Concentrations of Credit Risk and Significant Customers Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, investments and accounts receivable. The Company invests its excess cash with large financial institutions that the Company believes are of high credit quality. Cash and cash equivalents are invested in highly rated money market funds. At times, the Company’s cash balances with individual banking institutions are in excess of federally insured limits. The Company’s investments are invested in U.S. government agency bonds. The Company has not experienced any losses on its deposits of cash, cash equivalents or investments. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company performs ongoing assessments and credit evaluations of its customers to assess the collectability of the accounts based on a number of factors, including past transaction experience, age of the accounts receivable, review of the invoicing terms of the contracts, and recent communication with customers. The Company has not experienced significant credit losses from its accounts receivable. As of June 30, 2022 and December 31, 2021, one customer accounted for 15 % and 19 % of outstanding accounts receivable, respectively. During the three months ended June 30, 2022 and 2021, sales to one customer represented 24 % and 25 % of the Company’s total revenue, respectively. During the six months ended June 30, 2022 and 2021, sales to one customer (who was a related party during the 2021 period) represented 25 % and 25 % of the Company’s total revenue, respectively. Recently Adopted Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes by removing certain exceptions and clarifying and amending existing guidance. The guidance was adopted effective January 1, 2021 and did no t have a material impact on the condensed consolidated financial statements and disclosures. In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”), which requires that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. To achieve this, an acquirer may assess how the acquiree applied Topic 606 to determine what to record for the acquired revenue contracts. Generally, this should result in an acquirer recognizing and measuring the acquired contract assets and contract liabilities consistent with how they were recognized and measured in the acquiree’s financial statements. The guidance was adopted effective July 1, 2021 and impacted the accounting of acquired deferred revenue for the Conversa and SilverCloud acquisitions that occurred in August 2021. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (‘‘ASU 2016-13’’), which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss model. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. These changes may result in earlier recognition of credit losses. In November 2018, the FASB issued ASU No. 2018-19, Codification Improvements to Topic 326, Financial Instruments—Credit Losses , which narrowed the scope and changed the effective date for non-public entities for ASU 2016-13. The FASB subsequently issued supplemental guidance within ASU No. 2019-05, Financial Instruments—Credit Losses (Topic 326): Targeted Transition Relief (‘‘ASU 2019-05’’). ASU 2019-05 provides an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis. The Company adopted ASU 2016-13 and the related clarifications in 2021 . The adoption did no t have a material effect on the Company’s consolidated financial statements.

Revenue

Revenue	6 Months Ended
	Jun. 30, 2022
Revenue from Contract with Customer [Abstract]
Revenue	3. Revenue The following table presents the Company’s revenues disaggregated by revenue source: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Platform subscription $ 29,592 $ 26,780 $ 58,283 $ 51,376 Visits 29,750 27,532 60,486 55,353 Other 5,174 5,905 9,979 11,087 Total Revenue $ 64,516 $ 60,217 $ 128,748 $ 117,816 Accounts Receivable, Net Accounts receivable primarily consist of amounts billed currently due from customers. Accounts receivable are presented net of an allowance for credit losses, which is an estimate of amounts that may not be collectible. In determining the amount of the allowance at each reporting date, the Company makes judgments about general economic conditions, historical write-off experience and any specific risks identified in customer collection matters, including the aging of unpaid accounts receivable and changes in customer financial conditions. Account balances are written off after all means of collection are exhausted and the potential for non-recovery is determined to be probable. Adjustments to the allowance for credit losses are recorded as general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss. Changes in the allowance for credit losses were as follows: Six Months Ended June 30, 2022 Year Ended December 31, 2021 Allowance for credit losses, beginning of the $ 1,809 $ 1,556 Provisions ( 308 ) 714 Write-offs ( 49 ) ( 461 ) Allowance for credit losses, end of the period $ 1,452 $ 1,809 The Company has rights to consideration for services completed but not billed at the reporting date. Unbilled receivables are classified as receivables when the Company has the right to invoice the customer. The amount of unbilled accounts receivable included within accounts receivable on the consolidated balance sheet was $ 4,339 and $ 5,697 as of June 30, 2022 and December 31, 2021, resp ectively. The amount of unbilled accounts receivable included within other assets on the consolidated balance sheet was zero as of June 30, 2022 and $ 781 as of December 31, 2021, respectively. Deferred Revenue Contract liabilities consist of deferred revenue and include billings in advance of performance under the contract. Such amounts are recognized as revenue over the contractual period. For the three months ended June 30, 2022 and 2021, the Company recognized revenue of $ 16,845 and $ 21,238 , respectively, that was included in the corresponding contract liability balance at the beginning of the periods presented. For the six months ended June 30, 2022 and 2021, the Company recognized revenue of $ 39,992 and $ 39,146 , respectively, that was included in the corresponding contract liability balance at the beginning of the periods presented. Changes in the Company’s deferred revenue balance for the six months ended June 30, 2022 and December 31, 2021 were as follows: Six Months Ended June 30, 2022 Year Ended December 31, 2021 Total deferred revenue, beginning of the period $ 75,896 $ 74,800 Additions 50,690 123,717 Recognized ( 57,838 ) ( 122,621 ) Total deferred revenue, end of the period $ 68,748 $ 75,896 Current deferred revenue 63,971 68,841 Non-current deferred revenue 4,777 7,055 Total $ 68,748 $ 75,896 Transaction Price Allocated to Remaining Performance Obligations As of June 30, 2022 and December 31, 2021, the aggregate amount of the transaction price allocated to remaining performance obligations was $ 192,836 and $ 219,893 , respectively. The substantial majority of the unsatisfied performance obligations will be satisfied over the next three years . As it pertains to the June 30, 2022 amount, the Company expects to recognize 45 % of the transaction price in the 12 month period ended June 30, 2023, in its condensed consolidated statement of operations and comprehensive loss with the remainder recognized thereafter.

National Telehealth Network

National Telehealth Network	6 Months Ended
	Jun. 30, 2022
Equity Method Investments and Joint Ventures [Abstract]
National Telehealth Network	4. National Telehealth Network In 2012, the Company and an affiliate of Anthem, Inc. formed NTN to expand the availability and adoption of telemedicine. The Company did not have a controlling financial interest in NTN, but it had the ability to exercise significant influence over the operating and financial policies of NTN. Therefore, the Company accounted for its investment in NTN using the equity method of accounting through December 31, 2015. On January 1, 2016, the Company made an additional investment in NTN, which increased its ownership percentage above 50 %. The Company also obtained the right to elect the Chairman of NTN, who has the ability to cast the tie-breaking vote in all decisions. Therefore, on January 1, 2016, the Company obtained control over NTN and has the power to direct the activities that most significantly impact NTN’s economic performance. This step-acquisition was accounted for as a business combination and the results of the operations of NTN from January 1, 2016, have been included in the Company’s condensed consolidated financial statements. However, because the Company owns less than 100 % of NTN, the Company recognizes net loss attributable to non-controlling interest in the condensed consolidated statements of operations and comprehensive loss equal to the percentage of the ownership interest retained in NTN by the respective non-controlling party. The proportionate share of the loss attributed to the non-controlling interest amounted to $ 507 and $ 277 for the three months ended June 30, 2022 and 2021, respectively. The proportionate share of the loss attributed to the non-controlling interest amounted to $ 723 and $ 894 for the six months ended June 30, 2022 and 2021, respectively. The carrying value of the non-controlling interest was $ 20,894 and $ 21,617 as of June 30, 2022 and December 31, 2021 , respectively.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	5. Fair Value Measurements Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: • Level 1—Quoted prices in active markets for identical assets or liabilities. • Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. • Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The following tables presents the Company’s fair value hierarchy for its assets and liabilities that are measured at fair value on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value: June 30, 2022 Level 1 Level 2 Level 3 Total Money market funds $ 167,560 $ — $ — $ 167,560 U.S government securities — 372,880 — $ 372,880 Total financial assets: $ 167,560 $ 372,880 $ — $ 540,440 December 31, 2021 Level 1 Level 2 Level 3 Total Money market funds $ 671,107 $ — $ — $ 671,107 Total financial assets: $ 671,107 $ — $ — $ 671,107 Contingent consideration $ — $ — $ 16,450 $ 16,450 Total financial liabilities: $ — $ — $ 16,450 $ 16,450 The Company’s cash equivalents were invested in money market funds and were valued based on Level 1 inputs. The Company’s investments consisted of U.S. government agency bonds and were valued based on Level 2 inputs. In determining the fair value of its U.S. government agency bonds, the Company relied on quoted prices for similar securities in active markets or other inputs that are observable or can be corroborated by observable market data. The Company has classified its net liability for contingent earnout considerations relating to the Acquisitions within Level 3 of the fair value hierarchy because the fair value is determined using significant unobservable inputs, which included the Monte Carlo method that uses key assumptions to model future revenue and costs of goods sold projections. A description of the Acquisitions is included within Note 7. The contingent earnout payments for each acquisition are based on the achievement of certain revenue thresholds. During the six months ended June 30, 2022 the fair value of the contingent earnout consideration decreased due to the Company signing an amendment to the agreement accelerating the determination of the Conversa revenue earn-out as of March 31, 2022 that resulted in the issuance of 1,020,964 shares of Class A Common Stock, and signing an amendment to the agreement accelerating the determination of the SilverCloud revenue earn-out as of May 11, 2022 that resulted in the issuance of 4,959,856 shares of Class A Common Stock, which resulted in a net accretion to the contingent considerations of $ 793 . Six Months Ended June 30, 2022 Beginning Balance as of January 1 $ 16,450 Accretion of contingent consideration 793 Fair value adjustment — Earned amount issued to shareholders in Class A Common Stock ( 17,243 ) Ending Balance $ — During the six months ended June 30, 2022 , there were no transfers between fair value measurement levels.

Investments

Investments	6 Months Ended
	Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Investments	6. Investments As of June 30, 2022 and December 31, 2021, the fair value of the Company’s investments by type of security was as follows: June 30, 2022 Amortized Gross Gross Fair Value Assets: U.S government securities $ 374,242 — $ ( 1,362 ) $ 372,880 $ 374,242 $ — $ ( 1,362 ) $ 372,880 December 31, 2021 Amortized Gross Gross Fair Value Assets: U.S government securities $ — $ — $ — $ — $ — $ — $ — $ —

Business Combinations

Business Combinations	6 Months Ended
	Jun. 30, 2022
Business Combinations [Abstract]
Business Combinations	7. Business Combinations On August 27, 2021 , the Company completed the acquisition of SilverCloud through a merger in which SilverCloud became a wholly-owned subsidiary of the Company. The cash consideration paid was $ 105,195 net of cash acquired of $ 12,239 . The stock consideration was comprised of 8.1 million shares of the Company’s Class A common stock valued at $ 85,571 , and escrow share consideration of $ 6,376 . SilverCloud is a leading digital mental health platform. The Company is obligated to pay an earn-out of up to $ 40,000 contingent upon SilverCloud achieving certain revenue thresholds for the year ending December 31, 2022. The Company estimated the fair value of the contingent consideration as of the acquisition date to be $ 29,360 . The contingent consideration is subject to remeasurement at each reporting date until December 31, 2022, with the remeasurement adjustment reported in the consolidated statement of operations and comprehensive loss. T he Company signed an amendment to the agreement accelerating the determination of the SilverCloud revenue earn-out as of May 11, 2022, which resulted in the issuance of 4,959,856 shares of Class A Common Stock. The acquisition was considered a stock acquisition for tax purposes and accordingly, the goodwill resulting from this acquisition is not tax deductible. The total acquisition related costs were $ 4,854 which included transaction costs from financial and legal advisors and other transaction related fees and were recognized as incurred in the Company’s consolidated statement of operations and comprehensive loss in general and administrative expenses. On August 9, 2021 , the Company completed the acquisition of Conversa through a merger in which Conversa became a wholly-owned subsidiary of the Company. The cash consideration paid was $ 51,331 net of cash acquired of $ 9,735 . The stock consideration was comprised of 4.7 million shares of the Company’s Class A common stock valued at $ 52,160 . Conversa is a leader in automated virtual healthcare. The Company is obligated to pay an earn-out of up to $ 30,000 contingent upon Conversa achieving certain integration thresholds in the first quarter of 2022, and certain revenue thresholds for the year ending December 31, 2022. The Company estimated the fair value of the contingent consideration as of the acquisition date to be $ 15,230 . The contingent consideration is subject to remeasurement at each reporting date until December 31, 2022, with the remeasurement adjustment reported in the consolidated statement of operations and comprehensive loss. The integration milestone was achieved in December 2021 and $ 15,000 was paid in January 2022. T he Company signed an amendment to the agreement accelerating the determination of the Conversa revenue earn-out as of March 31, 2022, which resulted in the issuance of 1,020,964 shares of Class A Common Stock. The acquisition was considered a stock acquisition for tax purposes and accordingly, the goodwill resulting from this acquisition is not tax deductible. The total acquisition related costs were $ 2,435 which included transaction costs from financial and legal advisors and other transaction related fees and were recognized as incurred in the Company’s consolidated statement of operations and comprehensive loss in general and administrative expenses. The Acquisitions were accounted for using the acquisition method of accounting, which requires, among other things, the assets acquired and the liabilities assumed be recognized at their fair values as of the acquisition date. The results of the Acquisitions were integrated within the consolidated financial statements commencing on the aforementioned acquisition dates. Actual revenue and losses of the Acquisitions since the acquisition date as well as pro forma combined results of operations for the Acquisitions have not been presented because the effect of the Acquisitions was not material to the Company’s consolidated financial results for the periods presented. The following table summarizes the preliminary fair value estimates of the assets acquired and liabilities assumed for the SilverCloud and Conversa acquisitions at the respective acquisition dates. The Company, with the assistance of a third-party valuation expert, estimated the preliminary fair value of the acquired tangible and intangible assets with significant estimates such as revenue projections. The allocation of the consideration transferred to the assets acquired and the liabilities assumed for the Acquisitions remains preliminary, and therefore can be revised as a result of additional information obtained due to completing the assessment of the tax attributes of the business combination. Additional adjustments may be recorded within the measurement period, which will not exceed one year from the acquisition date. Identifiable assets acquired and liabilities assumed: SilverCloud Conversa Health Purchase consideration: Cash consideration, net of cash acquired $ 105,195 $ 51,331 Stock consideration 85,571 52,160 Contingent consideration 29,360 15,230 Escrow share consideration 6,376 Working capital adjustment ( 300 ) ( 127 ) Total consideration transferred $ 226,202 $ 118,594 Allocation of consideration transferred: Accounts receivable $ 2,630 $ 3,651 Identifiable intangible assets 78,146 34,700 Other assets 491 4,604 Total assets acquired 81,267 42,955 Current liabilities 2,155 8,463 Deferred revenue 5,813 4,655 Other long-term liabilities 11,557 115 Total liabilities assumed 19,525 13,233 Goodwill $ 164,460 $ 88,872 $ 226,202 $ 118,594 The amount allocated to goodwill reflects the benefits the Company expects to realize from post-acquisition cross selling opportunities from integrating customer relationships and from the growth of the respective acquisitions’ operations. The following are the identifiable intangible assets acquired in the Acquisitions and their respective weighted average useful lives, as determined based on initial valuations. The estimated fair value of the Technology and Tradename was determined using a relief from royalty method and the estimated fair value of the Customer relationships was determined using the excess earnings method: SilverCloud Weighted Conversa Health Weighted Technology $ 34,996 5.0 $ 20,400 5.0 Tradename 10,800 7.0 4,200 5.0 Customer relationships 32,350 10.0 10,100 10.0 Total $ 78,146 $ 34,700

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	8. Goodwill and Intangible Assets Goodwill consisted of the following: Six Months Ended June 30, 2022 Beginning Balance as of January 1 $ 442,761 Goodwill acquired — Currency translation adjustments ( 8,921 ) Ending Balance $ 433,840 Identified intangible assets consisted of the following: Gross Accumulated Carrying Weighted June 30, 2022 Customer relationships $ 80,201 $ ( 20,852 ) $ 59,349 7.9 Contractor relationships 535 ( 268 ) 267 6.5 Tradename 13,688 ( 1,781 ) 11,907 5.5 Technology 88,575 ( 23,664 ) 64,911 4.7 $ 182,999 $ ( 46,565 ) $ 136,434 Gross Accumulated Carrying Weighted December 31, 2021 Customer relationships $ 81,053 $ ( 16,842 ) $ 64,211 8.2 Contractor relationships 535 ( 247 ) 288 7.0 Trade name 14,435 ( 706 ) 13,729 5.8 Technology 90,464 ( 16,283 ) 74,181 5.0 $ 186,487 $ ( 34,078 ) $ 152,409 Amortization expense related to intangible assets for the three months ended June 30, 2022 and 2021 was $ 6,328 and $ 1,928 , respectively. Amortization expense related to intangible assets for the six months ended June 30, 2022 and 2021 was $ 12,514 and $ 3,856 , respectively. Estimated future amortization expense of the identified intangible assets as of June 30, 2022, is as follows: 2022 $ 12,205 2023 24,361 2024 24,377 2025 24,361 2026 20,102 Thereafter 31,028 $ 136,434

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	6 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	9. Accrued Expenses and other current liabilities Accrued expenses and other current liabilities consist of the following: June 30, 2022 December 31, 2021 Employee compensation and benefits $ 15,876 $ 21,572 Professional services 14,983 8,766 Earned contingent consideration — 15,000 Provider services 4,483 5,473 Other 8,307 7,900 Total $ 43,649 $ 58,711

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2022
Stockholders' Equity Note [Abstract]
Stockholders' Equity	10. Stockholders’ Equity Undesignated Preferred Stock The Company’s Amended and Restated Certificate of Incorporation authorizes the issuance of 100,000,000 shares of undesignated preferred stock, par value of $ 0.01 per share, with rights and preferences, including voting rights, designated from time to time by the board of directors. No shares of preferred stock were issued or outstanding as of June 30, 2022 and December 31, 2021. Common Stock The Company’s Amended and Restated Certificate of Incorporation which authorizes capital stock of 1,000,000,000 shares of Class A common stock, par value $ 0.01 per share, 100,000,000 shares of Class B common stock, par value $ 0.01 per share, and 200,000,000 shares of Class C common stock, par value $ 0.01 per share. Except for the rights noted below, each share of Class A, Class B and Class C common stock have the same rights, are equal in all respects and are treated by us as one class of shares. Each share of Class A and Class C common stock is entitled to one vote per share on all matters presented for a vote, except that Class C common stock does not have the right to vote for elections of directors. Subject to certain conditions, Class B common stock is collectively entitled to a number of votes equal to the product of (x) 1.0408163 and (y) the total number of votes that would be cast at such time by the holders of the Class A and Class C common stock and any other preferred stock entitled to vote under the certificate of incorporation at such time (resulting in the Class B common stock collectively holding 51% of the total outstanding voting power) , and each share of Class B common stock will be entitled to a number of votes equal to the total number of votes held by all Class B common stock divided by the total number of then outstanding shares of Class B common stock. Shares of Class B and Class C common stock will be converted into shares of Class A common stock on a one-for-one basis upon the occurrence of certain events. Shares of Class B common stock will automatically convert on the first business day (i) after the date on which the outstanding shares of Class B common stock constitutes less than 5% of the aggregate number of shares of common stock then outstanding, (ii) after the date on which neither founder is serving as an executive officer or (iii) following seven years after the date the amended and restated certificate of incorporation becomes effective, provided that, such period may, to the extent permitted by law and applicable stock exchange rules, be extended for three years upon the affirmative vote of the holders of a majority of the voting power of the then-outstanding shares of Class A common stock entitled to vote thereon, voting separately as a class. Shares of Class C common stock will be convertible at the option of the holder upon determination that a Hart-Scott-Rodino Antitrust Improvements Act (“HSR”) filing is not necessary prior to the holder’s conversion of such shares or, if required, upon expiration or termination of the HSR waiting period. In the three and six months ended June 30, 2022, no shares of Class B common stock were converted to Class A common stock. As of June 30, 2022, the par value of the Class A, Class B and Class C shares was $ 2,403 , $ 275 , and $ 56 , respectively. Shares Shares Shares Class A 1,000,000,000 240,397,065 240,397,065 Class B 100,000,000 27,390,397 27,390,397 Class C 200,000,000 5,555,555 5,555,555 1,300,000,000 273,343,017 273,343,017 As of June 30, 2022 and December 31, 2021, the Company had reserved 74,437,861 and 61,989,749 shares of common stock for the exercise of outstanding stock options, the vesting of restricted stock units and the number of shares remaining available for future grant, respectively. Stock Plans and Stock Options The Company maintains the 2006 Employee, Director and Consultant Stock Plan as amended and restated (the “2006 Plan”) and 2020 Equity Incentive Plan (the “2020 Plan” together, the “Plans”) under which it has granted incentive stock options, non-qualified stock options, and restricted stock units to employees, officers, and directors of the Company. In connection with the adoption of the 2020 Plan, the then-remaining shares of common stock reserved for grant or issuance under the 2006 Plan became available for issuance under the 2020 Plan, and no further grants will be made under the 2006 Plan. The 2020 Plan is administered by the board of directors with respect to awards to non-employee directors and by the compensation committee, with respect to other participants, are collectively, referred to as the plan administrator. The exercise prices, vesting and other restrictions are determined at the discretion of the plan administrator. Options issued under the Plans are exercisable for periods not to exceed ten years, and vest and contain such other terms and conditions as specified in the applicable award document. Options to buy common stock are issued under the Plans, with exercise prices equal to the closing price of shares of the Company’s common stock on the New York Stock Exchange on the date of award. Activity under the Plans is as follows: Number of Weighted Weighted Average Aggregate Outstanding as of January 1, 2022 15,893,755 $ 4.81 5.9 $ 23,876 Granted — $ — Forfeited ( 953,627 ) $ 6.64 Expired ( 49,542 ) $ 5.63 Exercised ( 2,060,215 ) $ 2.13 Outstanding as of June 30, 2022 12,830,371 4.81 5.8 $ 6,198 Vested and expected to vest as of December 31, 2021 15,395,398 $ 4.61 5.8 $ 23,752 Vested and expected to vest as of June 30, 2022 12,630,154 $ 4.91 5.7 $ 6,194 Options exercisable as of December 31, 2021 13,407,882 $ 4.38 5.5 $ 23,120 Options exercisable as of June 30, 2022 11,634,556 $ 4.82 5.6 $ 6,198 No options were granted in the six months ended June 30, 2022 and 2021. Restricted Stock Units Activity for the restricted stock units is as follows: Shares Weighted Average Unvested as of January 1, 2022 11,718,813 $ 19.63 Granted 10,622,982 4.09 Vested ( 3,005,281 ) 12.55 Forfeited ( 1,787,601 ) 9.04 Unvested as of June 30, 2022 17,548,913 $ 7.75 The total grant date fair value of RSU’s granted for the six months ended June 30, 2022 was $ 43,456 . Restricted stock units vest over the service period of one to four years . The aggregate intrinsic value of restricted stock units vested for the six months ended June 30, 2022 and 2021 was $ 13,180 and $ 35,223 , respectively. Restricted Stock Units with a Market Condition In the six months ended June 30, 2022 the Company granted performance-based market condition share awards to certain members of the Company’s management team, which entitle these employees with the right to receive shares of common stock, upon achievement of certain market capitalization milestones measured over a rolling thirty day trading-period, subject to the satisfaction of the applicable service vesting conditions. The performance-based market condition share awards for management (other than the co-CEOs) consist of six tranches with six separate specified award values that become payable upon achievement of certain market capitalization milestones, which can result in a vesting range of up to 10,423,674 shares. Also in 2022 the Company granted performance-based market condition share awards to the co-CEOs, which entitle these employees with the right to receive shares of common stock, upon achievement of certain market capitalization milestones measured over a rolling thirty day trading-period, subject to the satisfaction of the applicable service vesting conditions. The performance-based market condition share awards for the co-CEOs consist of eight tranches with eight separate specified award values that become payable upon achievement of certain market capitalization milestones (subject to specified vesting caps during each of the first two years of the performance period), which can result in a vesting range of up to 7,500,000 shares for each co-CEO. As of June 30, 2022 , the performance-based market conditions for the awards to management and the co-CEOs have not been met. These performance-based market condition share awards have a performance period of three years . Shares Weighted Average Unvested as of January 1, 2022 — $ — Granted 25,423,674 2.21 Vested — — Cancelled/Forfeited ( 1,568,889 ) 2.62 Unvested as of June 30, 2022 23,854,785 $ 2.18 The total grant-date fair value of performance-based market condition share awards granted during the six months ended June 30, 2022 was $ 56,109 million and no performance-based market condition share awards were granted during the six months ended June 30, 2021. The weighted average estimated fair value of the performance-based market condition share awards granted during the six months ended June 30, 2022 was determined using a Monte-Carlo valuation simulation, with the following most significant weighted-average assumptions: Six Months Ended June 30, 2022 Risk-free rate 2.28 % Term to end of performance period (yrs) 3 years Valuation date stock price $ 3.43 Expected volatility 75 % Expected dividend yield 0 % 2020 Employee Stock Purchase Plan During the six months ended June 30, 2021 , the Company had no t issued any shares under the ESPP. During the six months ended June 30, 2022, the Company issued 425,114 shares under the ESPP. As of June 30, 2022 4,779,994 shares remained available for issuance. Stock-Based Compensation Stock-based compensation expense was classified in the condensed consolidated statements of operations and comprehensive loss as follows: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Cost of revenues $ 426 $ 521 $ 761 $ 910 Research and development 2,699 2,171 4,881 3,678 Selling and marketing 1,304 2,100 3,099 3,989 General and administrative 10,478 5,934 18,251 10,791 Total $ 14,907 $ 10,726 $ 26,992 $ 19,368 As of June 30, 2022, the unrecognized stock-based compensation expense related to unvested common stock-based awards was $ 116,818 , which is expected to be recognized over a weighted-average period of 2.6 years.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies Indemnification The Company’s arrangements generally include certain provisions for indemnifying customers against third-party claims asserting infringement of certain intellectual property rights in the ordinary course of business. The Company also regularly indemnifies customers against third-party claims that the company’s products or services breach applicable law or regulation or from claims resulting from a breach of the business associate agreement in place with the customer. In addition, the Company indemnifies its officers, directors and certain key employees while they are serving in good faith in their capacities. Through June 30, 2022 and December 31, 2021 , there have been no claims under any indemnification provisions. Litigation From time to time, and in the ordinary course of business, the Company may be subject to various claims, charges, and litigation. On September 14, 2020, the Company received a letter from Teladoc Health, Inc. ("Teladoc") alleging that certain of the Company’s cart products and associated peripherals infringe upon their patents. On October 12, 2020, Teladoc filed a claim against the Company related to these allegations. On June 30, 2022, the claim was dismissed pursuant to a confidential settlement between the parties. As of June 30, 2022 and December 31, 2021 , the Company did no t have any pending claims, charges or litigation that it expects would have a material adverse effect on its consolidated financial position, results of operations or cash flows.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	12. Income Taxes As a result of the Company’s history of net operating losses (“NOL”), the Company continues to maintain a full valuation allowance against its domestic net deferred tax assets. For the three and six months ended June 30, 2022, the Company recognized an income tax expense of $ 461 and $ 129 , primarily due to state and foreign income tax. During the three and six months ended June 30, 2021 , the Company recorded income tax expense of $ 103 and $ 412 , primarily due to estimated state and foreign income taxes.

Related-Party Transactions

Related-Party Transactions	6 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
Related-Party Transactions	13. Related-Party Transactions Philips Holding USA, Inc. Philips Holding USA, Inc. (“Philips”) was determined to be a related party through June 2021, because a member of the Company’s board of directors was the Business Leader of Philips Population Health Management. In the three and six months ended June 30, 2021 the Company recognized revenue of $ 758 and 1,658 , respectively from contracts with this customer. Anthem Inc. Anthem Inc. (“Anthem”) was determined to be a related party through February 2021, because a member of the Company’s board of directors served as the Vice President of Anthem. Prior to that director's departure from Anthem in February 2021 the Company recognized revenue of $ 7,218 from contracts with this customer. Cleveland Clinic Cleveland Clinic is a related party because a member of the Company’s board of directors is an executive advisor to Cleveland Clinic. As of June 30, 2022 and December 31, 2021, the Company held total deferred revenue of $ 261 and $ 456 , respectively from contracts with this customer. As of June 30, 2022 and December 31, 2021, amounts due from Cleveland Clinic were $ 82 and $ 441 , respectively. During the three months ended June 30, 2022 and 2021, the Company recognized revenue of $ 694 and $ 279 , respectively, from contracts with this customer. During the six months ended June 30, 2022 and 2021, the Company recognized revenue of $ 1,454 and $ 530 , respectively, from contracts with this customer. CCAW, JV LLC CCAW, JV LLC is a related party because it is a joint venture formed between the Company and Cleveland Clinic for which the Company has a minority owned interest in. During the year ended December 31, 2020, the Company made an initial investment in CCAW, JV LLC of $ 2,940 for its less than 50 % interest in the joint venture. During the three months ended June 30, 2021 , the Company made a capital contribution of $ 2,548 , related to a portion of the phase one capital commitment. During the three months ended June 30, 2022 the Company made a capital contribution of $ 1,960 related to a portion of the phase one capital commitment. During the three months ended June 30, 2022 and 2021 the Company recognized revenue of $ 469 and $ 412 from contracts with this customer, respectively. During the six months ended June 30, 2022 and 2021, the Company recognized revenue of $ 923 and $ 874 from contracts with this customer, respectively. As of June 30, 2022 and December 31, 2021, the Company held total deferred revenue of $ 622 and $ 1,426 , respectively, from contracts with this customer. As of June 30, 2022 and December 31, 2021, amounts due from CCAW, JV LLC were zero and $ 1,613 .

Net Loss per Share

Net Loss per Share	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Net Loss per Share	14. Net Loss per Share Basic and diluted net loss per share attributable to common stockholders was calculated as follows: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Numerator: Net loss $ ( 69,652 ) $ ( 38,136 ) $ ( 139,905 ) $ ( 77,941 ) Net loss attributable to non-controlling interest ( 507 ) ( 277 ) ( 723 ) ( 894 ) Net loss attributable to American Well Corporation $ ( 69,145 ) $ ( 37,859 ) $ ( 139,182 ) $ ( 77,047 ) Denominator: Weighted-average common shares outstanding 273,320,740 249,366,652 273,615,031 246,471,733 Net loss per share attributable to common $ ( 0.25 ) $ ( 0.15 ) $ ( 0.51 ) $ ( 0.31 ) The Company’s potential dilutive securities, which include stock options, convertible preferred stock and unvested restricted stock units, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares equivalents presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Unvested restricted stock units 14,856,621 7,724,006 14,856,621 7,724,006 Unvested performance market-based stock units 23,854,785 — 23,854,785 — Options to purchase shares of common stock 12,830,371 17,562,754 12,830,371 17,562,754 51,541,777 25,286,760 51,541,777 25,286,760

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary for the fair statement of the Company’s the financial position, results of operations and cash flows at the dates and for the periods indicated. The interim results for the three and six months ended June 30, 2022 are not necessarily indicative of results for the full 2022 calendar year or any other future interim periods. The information included in the interim financial statements should be read in conjunction with the annual consolidated financial statements and accompanying notes included in the Form 10-K. The unaudited condensed consolidated financial statements include the accounts of American Well Corporation, its wholly-owned subsidiaries, those of professional corporations, which represent variable interest entities in which American Well has an interest and is the primary beneficiary (“PC”), and National Telehealth Network (“NTN”), an entity in which American Well controls fifty percent or more of the voting shares (see Note 4). Intercompany accounts and transactions have been eliminated in consolidation. The Company’s reporting currency is the U.S. dollar. The Company determines the functional currency of each subsidiary based on the currency of the primary economic environment in which each subsidiary operates. Items included in the financial statements of such subsidiaries are measured using that functional currency. Foreign currency denominated monetary assets and liabilities are remeasured into U.S. dollars at current exchange rates and foreign currency denominated nonmonetary assets and liabilities are remeasured into U.S. dollars at historical exchange rates. Gains or losses from foreign currency remeasurement and settlements are included in interest income and other income (expense), net in the condensed consolidated statements of operations and comprehensive loss. For consolidated entities where American Well owns or is exposed to less than 100 % of the economics, the net loss attributable to noncontrolling interests is recorded in the condensed consolidated statements of operations and comprehensive loss equal to the percentage of the economic or ownership interest retained in each entity by the respective non-controlling party. The noncontrolling interests are presented as a separate component of stockholders’ deficit in the condensed consolidated balance sheets.
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reported periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, revenue recognition, the estimated customer relationship period that is used in the amortization of deferred contract acquisition costs, the valuation of assets and liabilities acquired in business combinations, the useful lives of intangible assets and property and equipment and the valuation of common stock. The Company bases its estimates on historical experience, known trends, and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. Due to the COVID-19 global pandemic, the global economy and financial markets have been disrupted and there is a significant amount of uncertainty about the length and severity of the consequences caused by the pandemic. The Company has considered information available to it as of the date of issuance of these financial statements and has not experienced any significant impact to its estimates and assumptions as a result of the COVID-19 pandemic. On an ongoing basis, the Company will continue to closely monitor the COVID-19 impact on its estimates and assumptions.
Segment Information	Segment Information The Company’s chief operating decision makers (CODMs), its two Chief Executive Officers, review financial information presented on a consolidated basis for purposes of allocating resources and evaluating financial performance. The Company operates and manages its business as one reportable and operating segment. In addition, substantially all of the Company’s revenue and long-lived assets are attributable to operations in the United States for all periods presented.
Variable Interest Entities	Variable Interest Entities The Company evaluates its ownership, contractual and other interests in entities to determine if it has any variable interest in a variable interest entity (“VIE”). These evaluations are complex and involve judgment. If the Company determines that an entity in which it holds a contractual or ownership interest is a VIE and that the Company is the primary beneficiary, the Company consolidates such entity in its condensed consolidated financial statements. The primary beneficiary of a VIE is the party that meets both of the following criteria: (i) has the power to make decisions that most significantly affect the economic performance of the VIE; and (ii) has the obligation to absorb losses or the right to receive benefits that in either case could potentially be significant to the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company’s involvement with a VIE will cause the consolidation conclusion to change. Changes in consolidation status are applied prospectively. The aggregate carrying value of total assets and total liabilities included on the condensed consolidated balance sheets for the PCs after elimination of intercompany transactions were $ 26,879 and $ 1,508 , respectively, as of June 30, 2022 and $ 29,770 and $ 1,485 , respectively as of December 31, 2021. Total revenue included on the condensed consolidated statements of operations and comprehensive loss for the PCs after elimination of intercompany transactions was $ 17,400 and $ 17,585 for the three ended June 30, 2022 and 2021, respectively. Net loss included on the condensed consolidated statements of operations and comprehensive loss was not material for the three months ended June 30, 2022 and 2021. Total revenue included on the condensed consolidated statements of operations and comprehensive loss for the PCs after elimination of intercompany transactions was $ 35,792 and $ 35,154 for the six months ended June 30, 2022 and 2021, respectively. Net loss included on the condensed consolidated statements of operations and comprehensive loss was not material for the six months ended June 30, 2022 and 2021
Investment in Minority Owned Joint Venture	Investment in Minority Owned Joint Venture The Company and Cleveland Clinic partnered to form a joint venture, under the name CCAW, JV LLC, to provide broad access to comprehensive and high acuity care services via digital care delivery. The Company does not have a controlling financial interest in CCAW, JV LLC, but it does have the ability to exercise significant influence over the operating and financial policies of CCAW, JV LLC. Therefore, the Company accounts for its investment in CCAW, JV LLC using the equity method of accounting. The joint venture is considered a variable interest entity under ASC 810-10, but the Company is not the primary beneficiary as it does not have the power to direct the activities of the joint venture that most significantly impact its performance. The Company’s evaluation of ability to impact performance is based on Cleveland Clinic’s managing directors and Cleveland Clinic’s ability to appoint and remove the chairperson who has the ability to cast the tie breaking vote on the most significant activities. In 2020 the Company contributed $ 2,940 as its initial investment for a 49 % interest in CCAW, JV LLC. The agreement also requires aggregate total capital contributions by the Company up to an additional $ 11,800 in two phases, which is yet to be defined. During the three months ended March 31, 2021, the Company made a capital contribution of $ 2,548 , related to a portion of the phase one capital commitment. In April 2022 the Company made a capital contribution of $ 1,960 related to a portion of the phase one capital commitment. For the three months ended June 30, 2022 and 2021, the Company recognized a loss of $ 551 and $ 722 as its proportionate share of the joint venture’s results of operations, respectively. For the six months ended June 30, 2022 and 2021, the Company recognized a loss of $ 762 and $ 1,541 , respectively. Accordingly, the carrying value of the equity method investment as of June 30, 2022 and December 31, 2021 was $ 1,366 and $ 168 , respectively.
Concentrations of Credit Risk and Significant Customers	Concentrations of Credit Risk and Significant Customers Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, investments and accounts receivable. The Company invests its excess cash with large financial institutions that the Company believes are of high credit quality. Cash and cash equivalents are invested in highly rated money market funds. At times, the Company’s cash balances with individual banking institutions are in excess of federally insured limits. The Company’s investments are invested in U.S. government agency bonds. The Company has not experienced any losses on its deposits of cash, cash equivalents or investments. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company performs ongoing assessments and credit evaluations of its customers to assess the collectability of the accounts based on a number of factors, including past transaction experience, age of the accounts receivable, review of the invoicing terms of the contracts, and recent communication with customers. The Company has not experienced significant credit losses from its accounts receivable. As of June 30, 2022 and December 31, 2021, one customer accounted for 15 % and 19 % of outstanding accounts receivable, respectively. During the three months ended June 30, 2022 and 2021, sales to one customer represented 24 % and 25 % of the Company’s total revenue, respectively. During the six months ended June 30, 2022 and 2021, sales to one customer (who was a related party during the 2021 period) represented 25 % and 25 % of the Company’s total revenue, respectively.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes by removing certain exceptions and clarifying and amending existing guidance. The guidance was adopted effective January 1, 2021 and did no t have a material impact on the condensed consolidated financial statements and disclosures. In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”), which requires that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. To achieve this, an acquirer may assess how the acquiree applied Topic 606 to determine what to record for the acquired revenue contracts. Generally, this should result in an acquirer recognizing and measuring the acquired contract assets and contract liabilities consistent with how they were recognized and measured in the acquiree’s financial statements. The guidance was adopted effective July 1, 2021 and impacted the accounting of acquired deferred revenue for the Conversa and SilverCloud acquisitions that occurred in August 2021. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (‘‘ASU 2016-13’’), which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss model. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. These changes may result in earlier recognition of credit losses. In November 2018, the FASB issued ASU No. 2018-19, Codification Improvements to Topic 326, Financial Instruments—Credit Losses , which narrowed the scope and changed the effective date for non-public entities for ASU 2016-13. The FASB subsequently issued supplemental guidance within ASU No. 2019-05, Financial Instruments—Credit Losses (Topic 326): Targeted Transition Relief (‘‘ASU 2019-05’’). ASU 2019-05 provides an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis. The Company adopted ASU 2016-13 and the related clarifications in 2021 . The adoption did no t have a material effect on the Company’s consolidated financial statements.

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Jun. 30, 2022
Revenue from Contract with Customer [Abstract]
Summary of Disaggregation of Revenue	The following table presents the Company’s revenues disaggregated by revenue source: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Platform subscription $ 29,592 $ 26,780 $ 58,283 $ 51,376 Visits 29,750 27,532 60,486 55,353 Other 5,174 5,905 9,979 11,087 Total Revenue $ 64,516 $ 60,217 $ 128,748 $ 117,816
Summary of Changes in the Allowance for Credit Losses	Changes in the allowance for credit losses were as follows: Six Months Ended June 30, 2022 Year Ended December 31, 2021 Allowance for credit losses, beginning of the $ 1,809 $ 1,556 Provisions ( 308 ) 714 Write-offs ( 49 ) ( 461 ) Allowance for credit losses, end of the period $ 1,452 $ 1,809
Summary of Significant Changes in the Company's Deferred Revenue	Changes in the Company’s deferred revenue balance for the six months ended June 30, 2022 and December 31, 2021 were as follows: Six Months Ended June 30, 2022 Year Ended December 31, 2021 Total deferred revenue, beginning of the period $ 75,896 $ 74,800 Additions 50,690 123,717 Recognized ( 57,838 ) ( 122,621 ) Total deferred revenue, end of the period $ 68,748 $ 75,896 Current deferred revenue 63,971 68,841 Non-current deferred revenue 4,777 7,055 Total $ 68,748 $ 75,896

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	The following tables presents the Company’s fair value hierarchy for its assets and liabilities that are measured at fair value on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value: June 30, 2022 Level 1 Level 2 Level 3 Total Money market funds $ 167,560 $ — $ — $ 167,560 U.S government securities — 372,880 — $ 372,880 Total financial assets: $ 167,560 $ 372,880 $ — $ 540,440 December 31, 2021 Level 1 Level 2 Level 3 Total Money market funds $ 671,107 $ — $ — $ 671,107 Total financial assets: $ 671,107 $ — $ — $ 671,107 Contingent consideration $ — $ — $ 16,450 $ 16,450 Total financial liabilities: $ — $ — $ 16,450 $ 16,450
Summary of Contingent Earnout Payments for Each Acquisition	Six Months Ended June 30, 2022 Beginning Balance as of January 1 $ 16,450 Accretion of contingent consideration 793 Fair value adjustment — Earned amount issued to shareholders in Class A Common Stock ( 17,243 ) Ending Balance $ —

Investments (Tables)

Investments (Tables)	6 Months Ended
	Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Debt securities, available-for-sale	As of June 30, 2022 and December 31, 2021, the fair value of the Company’s investments by type of security was as follows: June 30, 2022 Amortized Gross Gross Fair Value Assets: U.S government securities $ 374,242 — $ ( 1,362 ) $ 372,880 $ 374,242 $ — $ ( 1,362 ) $ 372,880 December 31, 2021 Amortized Gross Gross Fair Value Assets: U.S government securities $ — $ — $ — $ — $ — $ — $ — $ —

Business Combinations (Tables)

Business Combinations (Tables)	6 Months Ended
	Jun. 30, 2022
Business Combinations [Abstract]
Schedule of Identifiable Assets Acquired and Liabilities Assumed	Identifiable assets acquired and liabilities assumed: SilverCloud Conversa Health Purchase consideration: Cash consideration, net of cash acquired $ 105,195 $ 51,331 Stock consideration 85,571 52,160 Contingent consideration 29,360 15,230 Escrow share consideration 6,376 Working capital adjustment ( 300 ) ( 127 ) Total consideration transferred $ 226,202 $ 118,594 Allocation of consideration transferred: Accounts receivable $ 2,630 $ 3,651 Identifiable intangible assets 78,146 34,700 Other assets 491 4,604 Total assets acquired 81,267 42,955 Current liabilities 2,155 8,463 Deferred revenue 5,813 4,655 Other long-term liabilities 11,557 115 Total liabilities assumed 19,525 13,233 Goodwill $ 164,460 $ 88,872 $ 226,202 $ 118,594
Summary of Identifiable Intangible Assets Acquired and Weighted Average Useful Lives	The following are the identifiable intangible assets acquired in the Acquisitions and their respective weighted average useful lives, as determined based on initial valuations. The estimated fair value of the Technology and Tradename was determined using a relief from royalty method and the estimated fair value of the Customer relationships was determined using the excess earnings method: SilverCloud Weighted Conversa Health Weighted Technology $ 34,996 5.0 $ 20,400 5.0 Tradename 10,800 7.0 4,200 5.0 Customer relationships 32,350 10.0 10,100 10.0 Total $ 78,146 $ 34,700

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	Goodwill consisted of the following: Six Months Ended June 30, 2022 Beginning Balance as of January 1 $ 442,761 Goodwill acquired — Currency translation adjustments ( 8,921 ) Ending Balance $ 433,840
Schedule of Finite-Lived Intangible Assets	Identified intangible assets consisted of the following: Gross Accumulated Carrying Weighted June 30, 2022 Customer relationships $ 80,201 $ ( 20,852 ) $ 59,349 7.9 Contractor relationships 535 ( 268 ) 267 6.5 Tradename 13,688 ( 1,781 ) 11,907 5.5 Technology 88,575 ( 23,664 ) 64,911 4.7 $ 182,999 $ ( 46,565 ) $ 136,434 Gross Accumulated Carrying Weighted December 31, 2021 Customer relationships $ 81,053 $ ( 16,842 ) $ 64,211 8.2 Contractor relationships 535 ( 247 ) 288 7.0 Trade name 14,435 ( 706 ) 13,729 5.8 Technology 90,464 ( 16,283 ) 74,181 5.0 $ 186,487 $ ( 34,078 ) $ 152,409
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Estimated future amortization expense of the identified intangible assets as of June 30, 2022, is as follows: 2022 $ 12,205 2023 24,361 2024 24,377 2025 24,361 2026 20,102 Thereafter 31,028 $ 136,434

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	6 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
Summary of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consist of the following: June 30, 2022 December 31, 2021 Employee compensation and benefits $ 15,876 $ 21,572 Professional services 14,983 8,766 Earned contingent consideration — 15,000 Provider services 4,483 5,473 Other 8,307 7,900 Total $ 43,649 $ 58,711

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2022
Stockholders' Equity Note [Abstract]
Schedule of Common Stock	As of June 30, 2022, the par value of the Class A, Class B and Class C shares was $ 2,403 , $ 275 , and $ 56 , respectively. Shares Shares Shares Class A 1,000,000,000 240,397,065 240,397,065 Class B 100,000,000 27,390,397 27,390,397 Class C 200,000,000 5,555,555 5,555,555 1,300,000,000 273,343,017 273,343,017
Activity under Plans	Activity under the Plans is as follows: Number of Weighted Weighted Average Aggregate Outstanding as of January 1, 2022 15,893,755 $ 4.81 5.9 $ 23,876 Granted — $ — Forfeited ( 953,627 ) $ 6.64 Expired ( 49,542 ) $ 5.63 Exercised ( 2,060,215 ) $ 2.13 Outstanding as of June 30, 2022 12,830,371 4.81 5.8 $ 6,198 Vested and expected to vest as of December 31, 2021 15,395,398 $ 4.61 5.8 $ 23,752 Vested and expected to vest as of June 30, 2022 12,630,154 $ 4.91 5.7 $ 6,194 Options exercisable as of December 31, 2021 13,407,882 $ 4.38 5.5 $ 23,120 Options exercisable as of June 30, 2022 11,634,556 $ 4.82 5.6 $ 6,198
Summary of Unvested Restricted Stock Unit Activity	Activity for the restricted stock units is as follows: Shares Weighted Average Unvested as of January 1, 2022 11,718,813 $ 19.63 Granted 10,622,982 4.09 Vested ( 3,005,281 ) 12.55 Forfeited ( 1,787,601 ) 9.04 Unvested as of June 30, 2022 17,548,913 $ 7.75
Summary of Performance-based Market Condition Share Awards	Shares Weighted Average Unvested as of January 1, 2022 — $ — Granted 25,423,674 2.21 Vested — — Cancelled/Forfeited ( 1,568,889 ) 2.62 Unvested as of June 30, 2022 23,854,785 $ 2.18
Schedule of Weighted Average Assumptions used to Determine Estimated Fair Value of Performance-based Market Condition Share Awards Granted	The weighted average estimated fair value of the performance-based market condition share awards granted during the six months ended June 30, 2022 was determined using a Monte-Carlo valuation simulation, with the following most significant weighted-average assumptions: Six Months Ended June 30, 2022 Risk-free rate 2.28 % Term to end of performance period (yrs) 3 years Valuation date stock price $ 3.43 Expected volatility 75 % Expected dividend yield 0 %
Stock-Based Compensation Expense	Stock-based compensation expense was classified in the condensed consolidated statements of operations and comprehensive loss as follows: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Cost of revenues $ 426 $ 521 $ 761 $ 910 Research and development 2,699 2,171 4,881 3,678 Selling and marketing 1,304 2,100 3,099 3,989 General and administrative 10,478 5,934 18,251 10,791 Total $ 14,907 $ 10,726 $ 26,992 $ 19,368

Net Loss per Share (Tables)

Net Loss per Share (Tables)	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Summary of Basic and Diluted Net Loss Per Share Attributable To Common Stockholders	Basic and diluted net loss per share attributable to common stockholders was calculated as follows: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Numerator: Net loss $ ( 69,652 ) $ ( 38,136 ) $ ( 139,905 ) $ ( 77,941 ) Net loss attributable to non-controlling interest ( 507 ) ( 277 ) ( 723 ) ( 894 ) Net loss attributable to American Well Corporation $ ( 69,145 ) $ ( 37,859 ) $ ( 139,182 ) $ ( 77,047 ) Denominator: Weighted-average common shares outstanding 273,320,740 249,366,652 273,615,031 246,471,733 Net loss per share attributable to common $ ( 0.25 ) $ ( 0.15 ) $ ( 0.51 ) $ ( 0.31 )
Summary of Antidilutive Securities Excluded From Computation of Net Loss Per Share	The Company excluded the following potential common shares equivalents presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Unvested restricted stock units 14,856,621 7,724,006 14,856,621 7,724,006 Unvested performance market-based stock units 23,854,785 — 23,854,785 — Options to purchase shares of common stock 12,830,371 17,562,754 12,830,371 17,562,754 51,541,777 25,286,760 51,541,777 25,286,760

Organization and Description _2

Organization and Description of Business - Additional Information (Detail) - USD ($) $ in Thousands	Aug. 27, 2021	Aug. 09, 2021	Jun. 30, 2022
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Cash, cash equivalents and investments			$ 630,069
Conversa Health Inc. [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Effective date of acquisition		Aug. 09, 2021
Silver Cloud Health Holdings, Inc. [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Effective date of acquisition	Aug. 27, 2021

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Detail) $ in Thousands		3 Months Ended			6 Months Ended		12 Months Ended
	Apr. 13, 2022 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Jun. 30, 2022 USD ($) Segment	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Summary Of Significant Accounting Policies [Line Items]
Number of reportable segment | Segment					1
Number of operating segment | Segment					1
Total assets		$ 1,298,473			$ 1,298,473		$ 1,445,836
Total liabilities		137,580			137,580		$ 184,961
Payment to acquire interest in joint venture					1,960	$ 2,548
Share of the net profit loss in the operations of joint venture		$ (551)	$ (722)		$ (762)	$ (1,541)
Accounting Standards Update 2019-12 [Member]
Summary Of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]		true			true
Change in accounting principle, accounting standards update, adoption date		Jan. 01, 2021			Jan. 01, 2021
Change in accounting principle, accounting standards update, immaterial effect [true false]		true			true
Accounting Standards Update 2021-08 [Member]
Summary Of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]		true			true
Change in accounting principle, accounting standards update, adoption date		Jul. 01, 2021			Jul. 01, 2021
Accounting Standards Update 2016-13 [Member]
Summary Of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]		true			true
Change in accounting principle, accounting standards update, adoption date		Dec. 31, 2021			Dec. 31, 2021
Change in accounting principle, accounting standards update, immaterial effect [true false]		true			true
Customer Concentration Risk | Accounts Receivable [Member] | Related Party Customer One [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of net total revenue					15%		19%
Customer Concentration Risk | Revenue Benchmark [Member] | Related Party Customer One [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of net total revenue		24%	25%		25%	25%
Variable Interest Entity, Primary Beneficiary [Member]
Summary Of Significant Accounting Policies [Line Items]
Total assets		$ 26,879			$ 26,879		$ 29,770
Total liabilities		1,508			1,508		1,485
Total revenue		17,400	$ 17,585		35,792	$ 35,154
Variable Interest Entity, Primary Beneficiary [Member] | CCACV JV LLC [Member]
Summary Of Significant Accounting Policies [Line Items]
Payment to acquire interest in joint venture								$ 2,940
Percentage of ownership interest in joint venture								49%
Estimated additional total capital contributions necessary								$ 11,800
Additional capital contribution related to portion of phase one capital commitment	$ 1,960			$ 2,548
Share of the net profit loss in the operations of joint venture		(551)	$ (722)		(762)	$ (1,541)
Equity method investment carrying value		$ 1,366			$ 1,366		$ 168
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of economic or ownership interest in consolidated entities					100%

Revenue - Summary of Disaggrega

Revenue - Summary of Disaggregation of Revenue (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disaggregation of Revenue [Line Items]
Total Revenue	$ 64,516	$ 60,217	$ 128,748	$ 117,816
Platform Subscription [Member]
Disaggregation of Revenue [Line Items]
Total Revenue	29,592	26,780	58,283	51,376
Visits [Member]
Disaggregation of Revenue [Line Items]
Total Revenue	29,750	27,532	60,486	55,353
Others [Member]
Disaggregation of Revenue [Line Items]
Total Revenue	$ 5,174	$ 5,905	$ 9,979	$ 11,087

Revenue - Summary of Changes in

Revenue - Summary of Changes in the Allowance for Credit Losses (Detail) - USD ($) $ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Allowance for credit losses, beginning of the period	$ 1,809	$ 1,556	$ 1,556
Provisions	(308)	$ (57)	714
Write-offs	(49)		(461)
Allowance for credit losses, end of the period	$ 1,452		$ 1,809

Revenue - Additional Informatio

Revenue - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Revenue From Contract With Customer Line Items [Line Items]
Contract liability revenue recognized	$ 16,845	$ 21,238	$ 39,992	$ 39,146
Transaction price allocated to remaining performance obligations	$ 192,836		$ 192,836		$ 219,893
Performance obligation percentage of transaction price to recognized in the next twelve months	45%		45%
Other Assets [Member]
Revenue From Contract With Customer Line Items [Line Items]
Unbilled receivables noncurrent	$ 0		$ 0		781
Accounts Receivable [Member]
Revenue From Contract With Customer Line Items [Line Items]
Unbilled receivables current	$ 4,339		$ 4,339		$ 5,697

Revenue - Summary of Contract w

Revenue - Summary of Contract with Customer Asset and Liability (Detail) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Total deferred revenue, beginning of the period	$ 75,896	$ 74,800
Additions	50,690	123,717
Recognized	(57,838)	(122,621)
Total deferred revenue, end of the period	68,748	75,896
Contract with Customer, Liability, Current	63,971	68,841
Contract with Customer, Liability, Noncurrent	4,777	7,055
Total	$ 68,748	$ 75,896

Revenue - Summary of Contract_2

Revenue - Summary of Contract with Customer Liability Current and Non Current (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenue from Contract with Customer [Abstract]
Current deferred revenue	$ 63,971	$ 68,841
Non-current deferred revenue	4,777	7,055
Total	$ 68,748	$ 75,896	$ 74,800

Revenue - Additional Informat_2

Revenue - Additional Information (Detail1)	Jun. 30, 2022	Dec. 31, 2021
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-01-01
Revenue From Contract With Customer Line Items [Line Items]
Revenue remaining performance obligation expected timing of satisfaction		3 years
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-07-01
Revenue From Contract With Customer Line Items [Line Items]
Revenue remaining performance obligation expected timing of satisfaction	3 years

National Telehealth Network - A

National Telehealth Network - Additional Information (Detail) - NTN [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Jan. 01, 2016
Schedule of Equity Method Investments [Line Items]
Loss from equity method investments	$ 507	$ 277	$ 723	$ 894
Noncontrolling Interest [Member]
Schedule of Equity Method Investments [Line Items]
Non controlling interest carrying value	$ 20,894		$ 20,894		$ 21,617
Minimum [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage						50%
Maximum [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage						100%

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value of Assets and Liabilities Measured on Recurring Basis (Detail) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	$ 540,440	$ 671,107
Total financial liabilities		16,450
Money Market Funds [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	167,560	671,107
U.S Government Securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	372,880
Contingent Consideration [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial liabilities		16,450
Fair Value, Inputs, Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	167,560	671,107
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	167,560	671,107
Fair Value, Inputs, Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	372,880
Fair Value, Inputs, Level 2 [Member] | U.S Government Securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	$ 372,880
Fair Value, Inputs, Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial liabilities		16,450
Fair Value, Inputs, Level 3 [Member] | Contingent Consideration [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial liabilities		$ 16,450

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($)				3 Months Ended	6 Months Ended
	May 11, 2022	Aug. 27, 2021	Aug. 09, 2021	Mar. 31, 2022	Jun. 30, 2022
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Transfer from level one to level two fair value assets					$ 0
Transfer from level one to level three fair value assets					0
Transfer from level two to level one fair value assets					0
Transfer from level three to level one fair value assets					0
Silver Cloud Health Holdings, Inc. [Member] | Common Class A [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Number of shares issued	4,959,856	8,100,000
Conversa Health Inc. [Member] | Common Class A [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Net accretion to contingent considerations					$ 793,000
Number of shares issued			4,700,000	1,020,964

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Contingent Earnout Payments for Each Acquisition (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Fair Value Disclosures [Abstract]
Beginning Balance as of January 1	$ 16,450
Accretion of contingent consideration	793
Earned amount issued to shareholders in Class A Common Stock	$ (17,243)

Investments - Debt Securities,

Investments - Debt Securities, Available-For-Sale (Detail) $ in Thousands	Jun. 30, 2022 USD ($)
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 374,242
Gross Unrealized Losses	(1,362)
Fair Value	372,880
U.S government securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	374,242
Gross Unrealized Losses	(1,362)
Fair Value	$ 372,880

Business Combinations - Additio

Business Combinations - Additional Information (Detail) - USD ($) $ in Thousands				1 Months Ended	3 Months Ended
	May 11, 2022	Aug. 27, 2021	Aug. 09, 2021	Jan. 31, 2022	Mar. 31, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Earn-out contingent consideration						$ 16,450
Silver Cloud Health Holdings, Inc. [Member]
Business Acquisition [Line Items]
Effective date of acquisition		Aug. 27, 2021
Cash consideration paid		$ 105,195
Cash acquired from acquisition		12,239
Aggregate merger consideration, escrow share consideration		6,376
Earn-out contingent consideration		40,000
Fair value of contingent consideration of acquisition date		29,360
Acquisition related costs		$ 4,854
Silver Cloud Health Holdings, Inc. [Member] | Common Class A [Member]
Business Acquisition [Line Items]
Aggregate merger consideration, shares	4,959,856	8,100,000
Aggregate merger consideration, stock value		$ 85,571
Conversa Health Inc. [Member]
Business Acquisition [Line Items]
Effective date of acquisition			Aug. 09, 2021
Cash consideration paid			$ 51,331
Cash acquired from acquisition			9,735
Integration milestone payments				$ 15,000
Earn-out contingent consideration			30,000
Fair value of contingent consideration of acquisition date			15,230
Acquisition related costs			$ 2,435
Conversa Health Inc. [Member] | Common Class A [Member]
Business Acquisition [Line Items]
Aggregate merger consideration, shares			4,700,000		1,020,964
Aggregate merger consideration, stock value			$ 52,160

Business Combinations - Schedul

Business Combinations - Schedule of Identifiable Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	Aug. 27, 2021	Aug. 09, 2021	Jun. 30, 2022	Dec. 31, 2021
Allocation of consideration transferred:
Goodwill			$ 433,840	$ 442,761
Silver Cloud Health Holdings, Inc. [Member]
Purchase consideration:
Cash consideration paid	$ 105,195
Stock consideration	85,571
Contingent consideration	29,360
Escrow share consideration	6,376
Working capital adjustment	(300)
Total consideration transferred	226,202
Allocation of consideration transferred:
Accounts receivable	2,630
Identifiable intangible assets	78,146
Other assets	491
Total assets acquired	81,267
Current liabilities	2,155
Deferred revenue	5,813
Other long-term liabilities	11,557
Total liabilities assumed	19,525
Goodwill	164,460
Total purchase consideration	$ 226,202
Conversa Health Inc. [Member]
Purchase consideration:
Cash consideration paid		$ 51,331
Stock consideration		52,160
Contingent consideration		15,230
Working capital adjustment		(127)
Total consideration transferred		118,594
Allocation of consideration transferred:
Accounts receivable		3,651
Identifiable intangible assets		34,700
Other assets		4,604
Total assets acquired		42,955
Current liabilities		8,463
Deferred revenue		4,655
Other long-term liabilities		115
Total liabilities assumed		13,233
Goodwill		88,872
Total purchase consideration		$ 118,594

Business Combinations - Summary

Business Combinations - Summary of Identifiable Intangible Assets Acquired and Weighted Average Useful Lives (Detail) - USD ($) $ in Thousands	Aug. 27, 2021	Aug. 09, 2021
Silver Cloud Health Holdings, Inc. [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Identifiable intangible assets acquired	$ 78,146
Conversa Health Inc. [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Identifiable intangible assets acquired		$ 34,700
Technology [Member] | Silver Cloud Health Holdings, Inc. [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Identifiable intangible assets acquired	$ 34,996
Weighted Average Life (Years)	5 years
Technology [Member] | Conversa Health Inc. [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Identifiable intangible assets acquired		$ 20,400
Weighted Average Life (Years)		5 years
Tradename [Member] | Silver Cloud Health Holdings, Inc. [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Identifiable intangible assets acquired	$ 10,800
Weighted Average Life (Years)	7 years
Tradename [Member] | Conversa Health Inc. [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Identifiable intangible assets acquired		$ 4,200
Weighted Average Life (Years)		5 years
Customer relationships [Member] | Silver Cloud Health Holdings, Inc. [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Identifiable intangible assets acquired	$ 32,350
Weighted Average Life (Years)	10 years
Customer relationships [Member] | Conversa Health Inc. [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Identifiable intangible assets acquired		$ 10,100
Weighted Average Life (Years)		10 years

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Schedule of Goodwill (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Beginning Balance as of January 1	$ 442,761
Currency translation adjustments	(8,921)
Ending Balance	$ 433,840

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Schedule of finite lived Intangible Assets (Detail) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Finite Lived Intangible Assets [Line Items]
Gross Amount	$ 182,999	$ 186,487
Accumulated Amortization	(46,565)	(34,078)
Carrying Value	136,434	152,409
Customer relationships [Member]
Finite Lived Intangible Assets [Line Items]
Gross Amount	80,201	81,053
Accumulated Amortization	(20,852)	(16,842)
Carrying Value	$ 59,349	$ 64,211
Weighted Average Remaining Life	7 years 10 months 24 days	8 years 2 months 12 days
Contractor relationships [Member]
Finite Lived Intangible Assets [Line Items]
Gross Amount	$ 535	$ 535
Accumulated Amortization	(268)	(247)
Carrying Value	$ 267	$ 288
Weighted Average Remaining Life	6 years 6 months	7 years
Trade name [Member]
Finite Lived Intangible Assets [Line Items]
Gross Amount	$ 13,688	$ 14,435
Accumulated Amortization	(1,781)	(706)
Carrying Value	$ 11,907	$ 13,729
Weighted Average Remaining Life	5 years 6 months	5 years 9 months 18 days
Technology [Member]
Finite Lived Intangible Assets [Line Items]
Gross Amount	$ 88,575	$ 90,464
Accumulated Amortization	(23,664)	(16,283)
Carrying Value	$ 64,911	$ 74,181
Weighted Average Remaining Life	4 years 8 months 12 days	5 years

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 6,328	$ 1,928	$ 12,514	$ 3,856

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Schedule of Finite Lived Intangible Assets Future Amortization Expense (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
2022	$ 12,205
2023	24,361
2024	24,377
2025	24,361
2026	20,102
Thereafter	31,028
Carrying Value	$ 136,434	$ 152,409

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Employee compensation and benefits	$ 15,876	$ 21,572
Professional services	14,983	8,766
Earned contingent consideration		15,000
Provider services	4,483	5,473
Other	8,307	7,900
Total	$ 43,649	$ 58,711

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) $ / shares in Units, $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2022 USD ($) Tranche $ / shares shares	Jun. 30, 2021 USD ($) shares	Dec. 31, 2021 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Preferred stock authorized	100,000,000	100,000,000		100,000,000
Preferred stock per share | $ / shares	$ 0.01	$ 0.01		$ 0.01
Preferred stock, shares issued	0	0		0
Preferred stock, shares outstanding	0	0		0
Common stock authorized	1,300,000,000	1,300,000,000
Common stock reserve for issuance	74,437,861	74,437,861		61,989,749
Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of stock granted | $		$ 43,456
Aggregate intrinsic value of restricted stock units vested | $		$ 13,180	$ 35,223
Restricted Stock [Member] | Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units vest over the service period		1 year
Restricted Stock [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units vest over the service period		4 years
Performance-based Market Condition Share Awards [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of stock granted | $		$ 56,109,000
Performance period		3 years
Number of Unvested shares	23,854,785	23,854,785
Shares, granted		25,423,674	0
Performance-based Market Condition Share Awards [Member] | Certain Members [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Trading period		30 days
Number of tranches | Tranche		6
Performance-based Market Condition Share Awards [Member] | CO-CEOs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Trading period		30 days
Number of tranches | Tranche		8
Performance period		2 years
Performance-based Market Condition Share Awards [Member] | Maximum [Member] | Certain Members [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Unvested shares	10,423,674	10,423,674
Performance-based Market Condition Share Awards [Member] | Maximum [Member] | CO-CEOs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Unvested shares	7,500,000	7,500,000
2020 Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options, granted		0	0
2020 Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, issued under ESPP		425,114	0
Shares available for issuance		4,779,994
Equity Award Plan [Member] | Common Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation | $	$ 116,818	$ 116,818
Weighted-average period		2 years 7 months 6 days
Common Class A [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock authorized	1,000,000,000	1,000,000,000		1,000,000,000
Common stock per share | $ / shares	$ 0.01	$ 0.01		$ 0.01
Common stock, voting rights		one
Common stock per share | $ / shares	$ 2,403	$ 2,403
Common Class B [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock authorized	100,000,000	100,000,000		100,000,000
Common stock per share | $ / shares	$ 0.01	$ 0.01		$ 0.01
Common stock, voting rights		(x) 1.0408163 and (y) the total number of votes that would be cast at such time by the holders of the Class A and Class C common stock and any other preferred stock entitled to vote under the certificate of incorporation at such time (resulting in the Class B common stock collectively holding 51% of the total outstanding voting power)
Number of shares converted	0	0
Common stock per share | $ / shares	$ 275	$ 275
Common Class C [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock authorized	200,000,000	200,000,000		200,000,000
Common stock per share | $ / shares	$ 0.01	$ 0.01		$ 0.01
Common stock, voting rights		one
Common stock per share | $ / shares	$ 56	$ 56

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Common Stock (Detail) - shares	Jun. 30, 2022	Dec. 31, 2021
Class of Stock [Line Items]
Shares Authorized	1,300,000,000
Shares Issued	273,343,017
Shares Outstanding	273,343,017
Class A [Member]
Class of Stock [Line Items]
Shares Authorized	1,000,000,000	1,000,000,000
Shares Issued	240,397,065	229,402,453
Shares Outstanding	240,397,065	229,402,453
Class B [Member]
Class of Stock [Line Items]
Shares Authorized	100,000,000	100,000,000
Shares Issued	27,390,397	26,913,579
Shares Outstanding	27,390,397	26,913,579
Class C [Member]
Class of Stock [Line Items]
Shares Authorized	200,000,000	200,000,000
Shares Issued	5,555,555	5,555,555
Shares Outstanding	5,555,555	5,555,555

Stockholders' Equity - Activity

Stockholders' Equity - Activity under Plans (Detail) - 2020 Equity Incentive Plan [Member] $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Outstanding, beginning of period | shares	15,893,755
Number of Shares, Forfeited | shares	(953,627)
Number of Shares, Expired | shares	(49,542)
Number of Shares, Exercised | shares	(2,060,215)
Number of Shares, Outstanding, end of period | shares	12,830,371	15,893,755
Number of Shares, Vested and expected to vest | shares	12,630,154	15,395,398
Number of Shares, Options exercisable | shares	11,634,556	13,407,882
Number of Shares, Outstanding, Weighted Average Exercise Price, beginning of period | $ / shares	$ 4.81
Number of Shares, Forfeited, Weighted Average Exercise Price | $ / shares	6.64
Number of Shares, Expired, Weighted Average Exercise Price | $ / shares	5.63
Number of Shares, Exercised, Weighted Average Exercise Price | $ / shares	2.13
Number of Shares, Outstanding, Weighted Average Exercise Price, end of period | $ / shares	4.81	$ 4.81
Number of Shares,Vested and expected to vest, Weighted Average Exercise Price, end of period | $ / shares	4.91	4.61
Number of Shares, Options exercisable, Weighted Average Exercise Price, end of period | $ / shares	$ 4.82	$ 4.38
Number of Shares, Outstanding, Weighted Average Remaining Contractual Term (years)	5 years 9 months 18 days	5 years 10 months 24 days
Number of Shares, Vested and expected to vest, Weighted Average Remaining Contractual Term (years)	5 years 8 months 12 days	5 years 9 months 18 days
Number of Shares, Options exercisable, Weighted Average Remaining Contractual Term (years)	5 years 7 months 6 days	5 years 6 months
Number of Shares, Outstanding, Aggregate Intrinsic Value | $	$ 6,198	$ 23,876
Number of Shares, Vested and expected to vest, Aggregate Intrinsic Value | $	6,194	23,752
Number of Shares, Options exercisable, Aggregate Intrinsic Value | $	$ 6,198	$ 23,120

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Unvested Restricted Stock Unit Activity (Detail) - Restricted Stock Units [Member]	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Class of Stock [Line Items]
Shares, Unvested as of January 1, 2022 | shares	11,718,813
Shares, Granted | shares	10,622,982
Shares, Vested | shares	(3,005,281)
Shares, Cancelled/Forfeited | shares	(1,787,601)
Shares, Unvested as of June 30, 2022 | shares	17,548,913
Weighted Average Grant Date Fair Value, Unvested as of January 1, 2022 | $ / shares	$ 19.63
Weighted Average Grant Date Fair Value, Granted | $ / shares	4.09
Weighted Average Grant Date Fair Value, Vested | $ / shares	12.55
Weighted Average Grant Date Fair Value, Cancelled/Forfeited | $ / shares	9.04
Weighted Average Grant Date Fair Value, Unvested as of June 30, 2022 | $ / shares	$ 7.75

Stockholders' Equity - Summar_2

Stockholders' Equity - Summary of Performance-based Market Condition Share Awards (Detail) - Performance-based Market Condition Share Awards [Member] - $ / shares	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Class of Stock [Line Items]
Shares, Granted	25,423,674	0
Shares, Cancelled/Forfeited	(1,568,889)
Shares, Unvested as of June 30, 2022	23,854,785
Weighted Average Grant Date Fair Value, Granted	$ 2.21
Weighted Average Grant Date Fair Value, Cancelled/Forfeited	2.62
Weighted Average Grant Date Fair Value, Unvested as of June 30, 2022	$ 2.18

Stockholders' Equity - Schedu_2

Stockholders' Equity - Schedule of Weighted Average Assumptions used to Determine Estimated Fair Value of Performance-based Market Condition Share Awards Granted (Details) - Performance-based Market Condition Share Awards [Member]	6 Months Ended
	Jun. 30, 2022 $ / shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free rate	2.28%
Term to end of performance period (yrs)	3 years
Valuation date stock price	$ 3.43
Expected volatility	75%
Expected dividend yield	0%

Stockholders' Equity - Stock-Ba

Stockholders' Equity - Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expenses	$ 14,907	$ 10,726	$ 26,992	$ 19,368
Cost of revenues [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expenses	426	521	761	910
Research and development [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expenses	2,699	2,171	4,881	3,678
Selling and marketing [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expenses	1,304	2,100	3,099	3,989
General and administrative [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expenses	$ 10,478	$ 5,934	$ 18,251	$ 10,791

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Pending Litigation [Member]
Loss Contingencies [Line Items]
Pending Claims Number	0	0
Indemnification Agreement [Member]
Loss Contingencies [Line Items]
New Claims Filed, Number	0	0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Income tax expense	$ 461	$ 103	$ 129	$ 412

Related-Party Transactions - Ad

Related-Party Transactions - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Feb. 28, 2021	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Revenues recognized from related party				$ (57,838)		$ (122,621)
Deferred revenue		$ 68,748		68,748		75,896	$ 74,800
Payment to acquire interest in joint venture				1,960	$ 2,548
CCAW JV LLC [Member]
Related Party Transaction [Line Items]
Deferred revenue		622		622		1,426
Revenues recognized from related party		469	$ 412	923	874
Due from related parties		0		0		1,613
Payment to acquire interest in joint venture		1,960	2,548				$ 2,940
Equity method investment, ownership percentage							50%
Philips Holding USA Inc [Member]
Related Party Transaction [Line Items]
Revenues recognized from related party			758		1,658
Anthem Inc [Member]
Related Party Transaction [Line Items]
Revenues recognized from related party	$ 7,218
Cleveland Clinic [Member]
Related Party Transaction [Line Items]
Deferred revenue		261		261		456
Revenues recognized from related party		694	$ 279	1,454	$ 530
Due from related parties		$ 82		$ 82		$ 441

Net Loss per Share - Schedule o

Net Loss per Share - Schedule of Earnings Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
Numerator:
Net loss	$ (69,652)	$ (70,253)	$ (38,136)	$ (39,805)	$ (139,905)	$ (77,941)
Net loss attributable to non-controlling interest	(507)		(277)		(723)	(894)
Net loss attributable to American Well Corporation	$ (69,145)		$ (37,859)		$ (139,182)	$ (77,047)
Denominator:
Weighted-average common shares outstanding, basic	273,320,740		249,366,652		273,615,031	246,471,733
Weighted-average common shares outstanding, diluted	273,320,740		249,366,652		273,615,031	246,471,733
Net loss per share attributable to common stockholders, basic	$ (0.25)		$ (0.15)		$ (0.51)	$ (0.31)
Net loss per share attributable to common stockholders, diluted	$ (0.25)		$ (0.15)		$ (0.51)	$ (0.31)

Net Loss per Share - Schedule_2

Net Loss per Share - Schedule of Antidilutive Securities Excluded From Computation of Earning Per Share (Detail) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	51,541,777	25,286,760	51,541,777	25,286,760
Unvested restricted stock units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	14,856,621	7,724,006	14,856,621	7,724,006
Unvested performance market-based stock units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	23,854,785		23,854,785
Options to purchase shares of common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	12,830,371	17,562,754	12,830,371	17,562,754